Search research articles
Contact Us
Filters
Showing results (31-40 of 65) with videos related to
Page
of 7
Sort By:
The Journal of Antimicrobial Chemotherapy
|
March 5, 2003
Activity of daptomycin against susceptible and multidrug-resistant Gram-positive pathogens collected in the SECURE study (Europe) during 2000-2001
Ian A Critchley, Deborah C Draghi, Daniel F Sahm, et al.
Antimicrobial Agents and Chemotherapy
|
May 23, 2002
Determining Linezolid's baseline in vitro activity in Canada using gram-positive clinical isolates collected prior to its national release
James A Karlowsky, Laurie J Kelly, Ian A Critchley, et al.
Annals of Clinical Microbiology and Antimicrobials
|
July 31, 2004
Emerging resistance among bacterial pathogens in the intensive care unit--a European and North American Surveillance study (2000-2002)
Mark E Jones, Deborah C Draghi, Clyde Thornsberry, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
February 16, 2005
Stable antimicrobial susceptibility rates for clinical isolates of Pseudomonas aeruginosa from the 2001-2003 tracking resistance in the United States today surveillance studies
James A Karlowsky, Mark E Jones, Clyde Thornsberry, et al.
Plos One
|
June 24, 2025
Ceftobiprole versus ceftriaxone ± linezolid in Community-Acquired Bacterial Pneumonia (CABP): Re-analysis of a randomized, phase 3 study using 2020 FDA guidance
Andrew F Shorr, Mark E Jones, Silke Friedmann, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
April 10, 2003
Factors associated with relative rates of antimicrobial resistance among Streptococcus pneumoniae in the United States: results from the TRUST Surveillance Program (1998-2002)
James A Karlowsky, Clyde Thornsberry, Mark E Jones, et al.
Annals of Clinical Microbiology and Antimicrobials
|
January 10, 2004
Tracking the implementation of NCCLS M100-S12 expanded-spectrum cephalosporin MIC breakpoints for nonmeningeal isolates of Streptococcus pneumoniae by clinical laboratories in the United States during 2002 and 2003
Ronald N Master, Deborah C Draghi, Mark E Jones, et al.
Annals of Clinical Microbiology and Antimicrobials
|
May 12, 2004
Prevalence and antimicrobial susceptibilities of bacteria isolated from blood cultures of hospitalized patients in the United States in 2002
James A Karlowsky, Mark E Jones, Deborah C Draghi, et al.
Diagnostic Microbiology and Infectious Disease
|
February 1, 2002
In vitro susceptibility of recent clinical isolates of pneumococci to the investigational cephalosporin cefditoren
James A Karlowsky, Mark E Jones, Deborah C Draghi, et al.
Journal of Clinical Microbiology
|
July 5, 2003
Comparison of four antimicrobial susceptibility testing methods to determine the in vitro activities of piperacillin and piperacillin-tazobactam against clinical isolates of Enterobacteriaceae and Pseudomonas aeruginosa
James A Karlowsky, Mellany K Weaver, Clyde Thornsberry, et al.
Page
of 7
Search research articles
Search
Showing results (31-40 of 65) with videos related to
Sort By:
Page
of 7
The Journal of Antimicrobial Chemotherapy
|
March 5, 2003
Activity of daptomycin against susceptible and multidrug-resistant Gram-positive pathogens collected in the SECURE study (Europe) during 2000-2001
Ian A Critchley, Deborah C Draghi, Daniel F Sahm, et al.
Antimicrobial Agents and Chemotherapy
|
May 23, 2002
Determining Linezolid's baseline in vitro activity in Canada using gram-positive clinical isolates collected prior to its national release
James A Karlowsky, Laurie J Kelly, Ian A Critchley, et al.
Annals of Clinical Microbiology and Antimicrobials
|
July 31, 2004
Emerging resistance among bacterial pathogens in the intensive care unit--a European and North American Surveillance study (2000-2002)
Mark E Jones, Deborah C Draghi, Clyde Thornsberry, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
February 16, 2005
Stable antimicrobial susceptibility rates for clinical isolates of Pseudomonas aeruginosa from the 2001-2003 tracking resistance in the United States today surveillance studies
James A Karlowsky, Mark E Jones, Clyde Thornsberry, et al.
Plos One
|
June 24, 2025
Ceftobiprole versus ceftriaxone ± linezolid in Community-Acquired Bacterial Pneumonia (CABP): Re-analysis of a randomized, phase 3 study using 2020 FDA guidance
Andrew F Shorr, Mark E Jones, Silke Friedmann, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
April 10, 2003
Factors associated with relative rates of antimicrobial resistance among Streptococcus pneumoniae in the United States: results from the TRUST Surveillance Program (1998-2002)
James A Karlowsky, Clyde Thornsberry, Mark E Jones, et al.
Annals of Clinical Microbiology and Antimicrobials
|
January 10, 2004
Tracking the implementation of NCCLS M100-S12 expanded-spectrum cephalosporin MIC breakpoints for nonmeningeal isolates of Streptococcus pneumoniae by clinical laboratories in the United States during 2002 and 2003
Ronald N Master, Deborah C Draghi, Mark E Jones, et al.
Annals of Clinical Microbiology and Antimicrobials
|
May 12, 2004
Prevalence and antimicrobial susceptibilities of bacteria isolated from blood cultures of hospitalized patients in the United States in 2002
James A Karlowsky, Mark E Jones, Deborah C Draghi, et al.
Diagnostic Microbiology and Infectious Disease
|
February 1, 2002
In vitro susceptibility of recent clinical isolates of pneumococci to the investigational cephalosporin cefditoren
James A Karlowsky, Mark E Jones, Deborah C Draghi, et al.
Journal of Clinical Microbiology
|
July 5, 2003
Comparison of four antimicrobial susceptibility testing methods to determine the in vitro activities of piperacillin and piperacillin-tazobactam against clinical isolates of Enterobacteriaceae and Pseudomonas aeruginosa
James A Karlowsky, Mellany K Weaver, Clyde Thornsberry, et al.
Page
of 7